Imricor Secures US FDA Clearance for Pediatric Expansion of NorthStar, Vision-MR Systems
MT Newswires Live
Jul 02
Imricor Medical Systems (ASX:IMR) received US Food and Drug Administration (FDA) clearance to expand pediatric use of its NorthStar iMR navigation system and Vision-MR diagnostic catheter, according to a Thursday Australian bourse filing.
The approvals permit both devices to be marketed to patients of all ages, including children and young adults, especially those receiving care at more than 250 children's hospitals across the US, per the filing.
The company said its interventional magnetic resonance imaging approach may be beneficial in pediatric cardiology for congenital heart defects requiring repeated catheterizations, eliminating exposure to ionizing X-ray radiation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.